Amyloidosis Treatment Market: Market Size & Forecast 2026

Amyloidosis represents a complex group of disorders where amyloid proteins build up in organs, potentially causing life-threatening organ dysfunction. The market has shifted significantly in recent years with the approval of RNA-targeted therapies that address the underlying cause of hereditary and wild-type transthyretin amyloidosis, representing the first major advance in decades. North America and Europe currently dominate the market, driven by higher diagnosis rates, advanced healthcare infrastructure, and earlier access to newly approved therapies.

• •Market valued at approximately $4.6 billion in 2025, with projected growth to around $6.6 billion by the early 2030s depending on the study
• •Recent wave of novel targeted therapies has transformed treatment paradigms, particularly for ATTR amyloidosis
• •High unmet medical need due to historically limited effective treatment options beyond supportive care and chemotherapy

The primary growth catalyst is the expanding pipeline of targeted therapies including RNA interference drugs and antisense oligonucleotides that offer disease-modifying potential. Improved diagnostic technologies, including nuclear imaging and genetic screening, are enabling earlier and more accurate identification of amyloidosis subtypes, expanding the treatable patient population. Additionally, growing investment in rare disease research, favorable regulatory pathways such as orphan drug designations, and increasing reimbursement coverage are accelerating market expansion globally.

• •Launch of disease-modifying therapies for ATTR amyloidosis has created a new standard of care and expanded market size
• •Advancements in diagnostic imaging and biomarker testing are reducing time to diagnosis and identifying more patients
• •Orphan drug status and expedited regulatory pathways provide incentives for pharmaceutical investment in this rare disease space

The market is segmented primarily by treatment type, including chemotherapy, stem cell transplantation, targeted therapy, and supportive care, with targeted therapies representing the fastest-growing segment. Geographic analysis shows North America leading in market share due to advanced healthcare systems and early adoption of novel therapies, followed by Europe and emerging markets in Asia-Pacific where awareness and diagnostic capacity are improving. The ATTR amyloidosis segment, encompassing both hereditary and wild-type forms, currently represents the largest focus area for commercialized treatments.

• •Targeted therapies (RNAi, ASOs) and stem cell transplantation are key high-value segments, with chemotherapy declining in usage for certain subtypes
• •North America accounts for the largest regional market share, with strong presence in Europe and growing opportunities in Asia-Pacific
• •Cardiac and neurological amyloidosis subtypes represent the highest unmet need due to severity and historical lack of effective treatments

What are the recent trends and outlook?

The market is trending toward earlier intervention and broader subtype coverage, with clinical development increasingly focused on preventing disease progression rather than merely managing symptoms. Combination therapies and next-generation formulations with improved safety profiles are anticipated to address limitations of current treatments, particularly regarding injection-site reactions and long-term tolerability. Expanded screening programs in at-risk populations and improved reimbursement frameworks are expected to sustain strong market growth through 2030 and beyond.

• •Shift toward biomarker-driven early treatment and screening of at-risk family members is expanding the patient pool
• •Emerging subcutaneous formulations and next-generation RNA-targeting agents aim to improve convenience and reduce treatment burden
• •Market consolidation through mergers, acquisitions, and strategic partnerships is expected to continue as large pharma seeks rare disease capabilities